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First published July 23, 2010; doi:10.1152/ajpheart.01251.2009.—Endoglin
(CD105) is an integral membrane glycoprotein that serves as a coreceptor for
members of the transforming growth factor- superfamily of proteins. A major role
for endoglin in regulating transforming growth factor--dependent vascular remodel-
ing and angiogenesis has been postulated based on the following: 1) endoglin is the
gene mutated in hereditary hemorrhagic telangiectasia type 1, a disease character-
ized by vascular malformations; 2) endoglin knockout mice die at midgestation
because of defective angiogenesis; 3) endoglin is overexpressed in neoangiogenic
vessels, during inflammation, and in solid tumors; and 4) endoglin regulates the
expression and activity of endothelial nitric oxide synthase, which is involved in
angiogenesis and vascular tone. Besides the predominant form of the endoglin
receptor (long endoglin isoform), two additional forms of endoglin have been
recently reported to play a role in the vascular pathology and homeostasis: the
alternatively spliced short endoglin isoform and a soluble endoglin form that is
proteolytically cleaved from membrane-bound endoglin. The purpose of this review
is to underline the role that the different forms of endoglin play in regulating
angiogenesis, vascular remodeling, and vascular tone, as well as to analyze the
molecular and cellular mechanisms supporting these effects.
nitric oxide; vascular malformations; angiogenesis; development
ENDOGLIN (also known as CD105) is a type I integral membrane
glycoprotein that belongs to the zona pellucida (ZP) family of
proteins (64, 105). It is highly expressed on proliferating
vascular endothelial cells (ECs) (25, 119) and has been iden-
tified as an accessory receptor for transforming growth factor-
(TGF-) (30). The human ENDOGLIN (ENG) gene has been
localized to chromosome 9q34ter (53), and it is mutated in
hereditary hemorrhagic telangiectasia (HHT) type 1 (118).
Mice lacking endoglin die during embryonic development
because of defective angiogenesis (6, 23, 103), and endoglin
plays a major role in tumoral and nontumoral adult angiogen-
esis (13, 79). A soluble form of endoglin also plays a central
role in preeclampsia, a disease characterized by hypertension
and severe alterations in placental circulation (172). Overall,
these results support the view that endoglin has a pivotal
function in vascular development and disease (13, 50, 93, 158).
The purpose of this review is to critically assess the role of
endoglin in vascular function as well as the mechanisms
involved.
Structure of Endoglin
Human endoglin is a type I integral membrane protein with
a large extracellular domain (561 amino acids), a single hy-
drophobic transmembrane domain, and a short cytosolic do-
main (64) (Fig. 1A). The expression of two different alterna-
tively spliced isoforms, long (L) endoglin and short (S) endog-
lin, has been demonstrated in human and mouse tissues (12, 64,
130). Human S-endoglin and L-endoglin proteins vary from
each other in their cytoplasmic tails that contain 14 and 47
amino acids, respectively, with a sequence of only 7 residues
being specific for S-endoglin (Fig. 1B). Because L-endoglin is
the predominantly expressed isoform, unless stated otherwise,
the functional studies in this review will be referred to this
isoform. Endoglin is a highly glycosylated protein expressed as
a 180-kDa disulfide-linked homodimer (63). The primary
structure of endoglin suggests that there are five N-linked
glycosylation sites in the NH2-terminal domain and a probable
O-glycan domain, which are rich in serine and threonine
residues proximal to the membrane-spanning domain (64).
Human endoglin also contains an Arg-Gly-Asp (RGD) peptide
sequence (64) that is known as a cell recognition site for
numerous adhesive proteins present in the extracellular matrix
(ECM), but this motif is absent from mouse (60), porcine
(177), rat, and canine (105) endoglin proteins. Structurally,
endoglin belongs to the ZP family of proteins that share a ZP
domain of 260 amino acid residues in their extracellular
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region (81, 105). The three-dimensional structure of the extra-
cellular domain of endoglin at 25Å resolution, using single-
particle electron microscopy, has been elucidated (105). En-
doglin arranges as a dome made of antiparallel-oriented mono-
mers enclosing a cavity at one end. Each subunit comprises one
ZP domain in the juxtamembrane region. The NH2-terminal
domain does not show any significant homology to any other
protein family/domain and thereby has been named an “or-
phan” domain (Fig. 1, A, C, and D).
The cytosolic domain of endoglin is constitutively phosphor-
ylated, and it can be targeted by serine and threonine kinases
(89, 177), including the TGF- type I and II receptors (73, 83).
It has been shown that the endoglin phosphorylation status can
influence its subcellular localization (83) and cellular migration
(144). Endoglin cytoplasmic domain contains a consensus
postsynaptic density 95/Drosophila disk large/zonula occlu-
dens-1 (PDZ)-binding motif (Ser-Ser-Met-Ala) present at the
carboxyl terminus that mediates endoglin interaction with
several PDZ domain-containing proteins and endoglin phos-
phorylation of distal threonine residues (13).
Regulation of Endoglin Expression
The cellular and tissue distribution of endoglin suggests its
role in vascular development, angiogenesis, and vascular ho-
meostasis. Endoglin is expressed at low levels in resting ECs,
but it is highly expressed in vascular ECs at sites of active
angiogenesis, during embryogenesis (80, 131), and in inflamed
tissues and healing wounds (163), psoriatic skin (145), in-
flamed synovial arthritis (155), upon vascular injury (21), and
in tumor vessels (13, 25, 55, 119). Endoglin is also overex-
pressed after ischemia and reperfusion in the kidney (47),
hindlimbs (79), and heart (168). Endoglin is expressed not only
in ECs but also in several other cell types involved in the
cardiovascular system. For example, whereas endoglin expres-
sion is low in normal smooth muscle cells (2), its expression is
upregulated in vascular smooth muscle cells (VSMCs) of
human atherosclerotic plaques (36). Endoglin is expressed in
cardiac fibroblasts and modulates the profibrogenic actions of
angiotensin II (31). Endoglin is also expressed in other tissues
undergoing fibrosis such as the kidney (143) and liver (34).
Endoglin is present on monocytes, and it is upregulated during
the monocyte-macrophage transition (87). During the develop-
ment of the cardiovascular system, endoglin is found on the
vascular endothelium of human embryos during all develop-
mental stages from 4 wk onward, and it is transiently upregu-
lated on cushion tissue mesenchyme during heart septation
(135). Furthermore, an altered expression of endoglin was
observed in human fetuses with cardiac defects (9).
Fig. 1. Structural representation of endoglin. A: endoglin is a type I membrane protein with a large extracellular domain that contains a zona pellucida (ZP) domain
of 260 amino acids in the juxtamembrane region and an NH2-terminal (N-ter) orphan domain. Endoglin forms dimers and the corresponding monomers are
disulphide linked. Consensus motifs to attach N-linked glycans and O-linked glycans to the extracellular domain have been identified. The cytoplasmic domain
of endoglin is phosphorylated (P) at Ser/Thr residues and contains a consensus postsynaptic density 95/Drosophila disk large/zonula occludens-1 (PDZ)-binding
motif present at the carboxyl terminus (C-ter). The cytoplasmic (CYT), transmembrane (TM), and extracellular (EC) domains of the protein are indicated. The
scheme is not to scale. B: amino acid sequences from short (S)-endoglin and long (L)-endoglin cytoplasmic tails. Sequences that differ between L and S isoforms
are in blue. The PDZ-binding motif in L-endoglin is underlined. C and D: 3-dimensional model of endoglin. C: the atomic model predicted in silico shows the
presence of 3 different subdomains in red, yellow, and blue. The orphan domain contains amino acid residues Glu26-Ile359 (red), whereas the ZP domain
encompasses the fragment Gln360-Gly586. The ZP-N and ZP-C subdomains are colored in yellow and blue, respectively. The amino acid numbers corresponding
to the border regions of the globular domains are indicated. D: the electron microscopy density map of soluble endoglin (gray volume) allows the fitting of the
atomic model of dimeric endoglin. S-S-, disulfide bridge. Adapted from Llorca et al. (105) and used with permission.
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The mechanisms responsible for the increased endoglin
expression in activated vessels are probably multifactorial,
hypoxia, vascular injury, and related cytokines being the most
likely stimuli. In fact, endoglin expression is upregulated after
ischemia in the heart (168), kidney (47), and hindlimbs (79), as
well as upon arterial injury (21, 110). Also, in murine cerebral
microvascular ECs, hypoxia induces the expression of endog-
lin at both the mRNA and protein levels, and this induction is
regulated by p38 and probably JNK pathways (179). Further-
more, a hypoxia-responsive element downstream of the main
transcription start site of the endoglin gene has been charac-
terized. Thus, under hypoxic conditions, the hypoxia-inducible
factor-1 (HIF-1) complex binds a functional consensus hy-
poxia-responsive element in the endoglin gene promoter (146).
TGF- signaling, via Smad transcription factors, also potently
stimulates endoglin expression (20, 88, 142). By contrast,
tumor necrosis factor- decreases endoglin protein levels in
ECs (98). Whereas hypoxia alone moderately stimulates en-
doglin transcription, the addition of TGF-1 under hypoxic
conditions results in a transcriptional cooperation between both
signaling pathways, leading to a marked stimulation of endog-
lin expression. This synergic stimulation involves the forma-
tion of a transcriptional multicomplex containing Smad3/
Smad4, stimulating protein 1 (Sp1), and HIF-1, leading to a
cooperative effect of these factors on endoglin transcription
(146). Also, upon vascular injury, a transcriptional activation
of endoglin mediated by the cooperative interaction between
Sp1 and Krüppel-like factor 6 transcription factors has been
reported (21).
Modulation by Endoglin of TGF--Dependent Cell
Responses
Endoglin is an auxiliary TGF- receptor that modulates
TGF-1- and TGF-3- but not TGF-2-dependent responses
in several cell types. In human monocytic cells, TGF-1, but
not TGF-2, responses are abrogated in the presence of en-
doglin (88). In a variety of cell types, including myoblasts and
fibroblasts, endoglin opposes TGF-1-dependent responses
such as the inhibition of cellular proliferation (88), the expres-
sion of the ECM proteoglycan lumican (22), as well as the
increased expression of ECM components, including plasmin-
ogen activator inhibitor type 1 (PAI-1), collagen, or fibronectin
(46, 72, 88, 96, 125). Moreover, neutralizing anti-endoglin
antibodies or antisense oligonucleotides for endoglin enhance
the inhibitory effect of TGF- on proliferation and migration
(100, 152), whereas endoglin overexpression counteracts the
antiproliferative effect of TGF-1 in ECs (100). The inhibition
of endoglin expression on ECs increases the antiproliferative
effect of TGF-1 and enhances EC apoptosis induced by
hypoxia and TGF-1 (100, 101). These findings are compatible
with the fact that endoglin is markedly upregulated in the
proliferating endothelium of tissues undergoing angiogenesis
(13, 18, 25, 56, 85).
While it is widely accepted that endoglin is expressed at high
levels in proliferating ECs, the direct role of endoglin in
mediating EC proliferation and migration is controversial.
Several experimental evidences support the hypothesis that
endoglin promotes EC proliferation and migration (92). How-
ever, other authors have reported that an Eng/ EC line
proliferates faster than Eng/ control cells (128) and that
Eng/ progenitors can be expanded and differentiated in
culture (33). With the use of a mouse with a conditional
mutation in the Eng gene, it was shown that subcutaneous
Matrigel implants in adult mice were populated by reduced
numbers of new blood vessels compared with controls,
whereas their endoglin-deficient retinas exhibited increased
proliferation of ECs (112). These variable results suggest that
the endoglin role in cell proliferation might be context depen-
dent and they should be interpreted with caution.
Endoglin cytoplasmic and extracellular domains specifically
interact with those of the activin-like kinase 1 (ALK1), a
TGF- type I receptor (15). Also, the colocalization of endog-
lin and ALK1 has been demonstrated in vascular endothelia
(113). Moreover, studies using Eng/ and Eng/ embryonic
ECs indicate that endoglin promotes EC proliferation via the
TGF-/ALK1 pathway (92), suggesting the involvement of
endoglin and ALK1 in a common signaling pathway (15, 93,
157). Analyses of the downstream target genes regulated by
endoglin and ALK1 have been carried out by gene expression
fingerprinting of endoglin-deficient human ECs from HHT
patients with pathogenic mutations in either endoglin or ALK1
genes. These studies allowed the identification of hundreds of
downregulated and upregulated genes, including those in-
volved in angiogenesis, cytoskeleton organization, cell guid-
ance, intercellular connections, cell migration and prolifera-
tion, or nitric oxide (NO) synthesis (51, 159).
Role of Endoglin in Vascular Pathology
The importance of endoglin in vascular biology is reflected
by the fact that mutations in the ENG gene lead to a vascular
disease called the Rendu-Osler-Weber syndrome or HHT1
(118). HHT is an inherited autosomal-dominant and highly
penetrant disorder characterized by vascular dysplasias, fre-
quent episodes of epistaxis, mucocutaneous telangiectases, and
arteriovenous malformations (AVMs) of the lung, brain, liver,
and gastrointestinal tract (69). A second form of HHT (HHT2)
is caused by mutations in the gene coding for the TGF- type
I receptor known as activin receptor-like kinase-1 (ACVRL1 or
ALK1). Either of the two genes, ENG or ACVRL1, is mutated
in more than 90% of patients with HHT (1, 19, 52, 57, 94, 95).
Two additional loci for HHT have been mapped to chromo-
somes 5 and 7, but the corresponding mutant genes have not
been identified yet (10, 35). Moreover, a combined syndrome
of juvenile polyposis (JP) and HHT was described to be caused
by mutations in SMAD4 that encodes a transcription factor of
the TGF- signaling pathway (59). This combined syndrome
(JP-HHT) occurs only in 1 to 2% of persons clinically diag-
nosed with HHT, as evidenced by detected mutations in
SMAD4.
A common feature in HHT patients is the presence of
vascular lesions (telangiectases and AVMs) that lead to a loss
of the intervening capillary network that connects the arteriole
with the venule (24, 74). Interestingly, the frequency of pul-
monary AVMs in HHT2 (8%) is far less than in HHT1 (45%)
patients. Expression studies in lung vessels showed that en-
doglin and ALK1 have distinct expression profiles in the
pulmonary vasculature and are only coexpressed in the distal
(precapillary) arteries, distal veins, and capillaries, consistent
with the tendency for pulmonary AVMs to form in the distal
pulmonary vessels in HHT (113). Despite the important patho-
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logical implications of these lesions, the mechanisms by which
they are generated have not been fully elucidated. Because of
the predominant expression of endoglin in ECs, it is tempting
to speculate that an endoglin loss of function of the mutant
allele in this cell type is the cause of the lesion. One of the
functions described for endoglin is the protective role against
apoptosis in ECs subjected to hypoxia and TGF-1 stimuli
(101). Thus endoglin haploinsufficiency in HHT may lead to a
massive apoptosis in those capillary ECs where endoglin func-
tion is required for survival (Fig. 2). As a consequence of the
EC apoptosis, the capillary network gradually disappears and
only a preferential vessel remains that eventually becomes the
arteriovenous shunt (Fig. 3). An interesting question that arises
in HHT patients is why the vascular lesions appear only at
distinct sites within certain organs, rather than being present
throughout the body and in all organs/tissues. To explain this
finding, one can postulate the need for an external trigger, or
second hit, such as inflammation, infection, vascular injury,
ischemia, or trauma that synergizes with endoglin haploinsuf-
ficiency to generate the lesion. Of note, these potential hits can
upregulate endoglin expression (21, 34, 47, 90, 110, 146, 163,
167, 168), suggesting that endoglin function is required under
those stressing conditions. Experimental support for the second
hit hypothesis has been recently reported using a mouse with a
conditional mutation in Eng, demonstrating that AVMs de-
velop when an angiogenic stimulus is combined with endoglin
depletion (112). Thus, in the HHT setting, endoglin protein
levels may not reach the minimum threshold to achieve the
optimal function and may be critical to generate the vascular
lesion (Fig. 3).
Endoglin and Regulation of Angiogenesis
Angiogenesis is a complex and highly regulated physiolog-
ical homeostatic process by which the body maintains the
supply of oxygen and metabolites depending on the require-
ments of a given organ or tissue (3, 141). It involves the
formation of new vessels with two separate, but coordinated,
phases: activation and maturation. The whole process consists
of a series of EC responses to angiogenic stimulation; includ-
ing degradation of ECM, budding, proliferation, migration,
tube formation, maturation, and maintenance of quiescent en-
dothelium. It should be noted that ECs in normal quiescent
endothelium have a very low turnover rate, with a doubling
time of more than 1,000 days. Angiogenic endothelium, in
contrast, has a rapid turnover, and it has been termed “acti-
vated” endothelium (85). In the activation phase, new sprouts
form at distinct locations in the preexisting vessel. Sprout
formation is initiated by EC activation, degradation of the
ECM by ECs, followed by the development of a new bud from
the EC layer. This bud will elongate by EC proliferation and
migration toward the source of the angiogenic stimuli. The
process culminates with tube formation and maturation. The
maturation phase consists of a progressive decrease in EC
proliferation and the recruitment of mesenchymal cells to form
mural cells, which can be pericytes or VSMCs. Pericytes are
thought to stabilize capillaries, whereas VSMCs are critical for
arterial structure and function (3, 28, 76, 141).
These processes are driven by a complex interaction of
different growth factors such as vascular endothelial growth
factor (VEGF), fibroblast growth factor, and TGF- and their
specific receptors. This complexity is eventually combined
Fig. 2. Hypothetical model for the role of endoglin in endothelial cell apoptosis and its relevance in HHT vascular lesions. Under certain stimuli, such as TGF-
and hypoxia, endothelial cells undergo apoptosis that is prevented by the induced expression of endoglin in healthy subjects. In patients with hereditary
hemorrhagic telangiectasia (HHT), endoglin haploinsufficiency may lead to a massive apoptosis in endothelial cells where endoglin function is required for
survival leading to capillary regression. A cross section of an individual vessel is depicted with endothelial cells in red, pericytes in blue, and apoptotic endothelial
cells in pink.
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with other types of angiogenic stimuli such as hypoxia. The
directionality of new vessel growth is driven by leading endo-
thelial tip cells in response to guidance molecules. Recent
studies have shown how endothelial tip, stalk, and phalanx
cells form sprouts and how ECs arrange in tubular structures in
a highly organized way (28). Platelet-derived growth factor
signaling is important for the initial recruitment of mesenchy-
mal cells that differentiate to VSMCs in response to TGF-
signaling. Both the stimulatory and inhibitory effects of TGF-
on angiogenesis have been reported (129, 157). Whether
TGF- stimulates or inhibits these processes depends on the
experimental conditions. For example, low doses of TGF- in
vitro (0.25–0.50 ng/ml) stimulate EC proliferation and migra-
tion, whereas higher doses show an inhibitory effect, leading to
EC quiescence (17, 68, 91).
A major evidence for the pivotal role of endoglin in angio-
genesis is that mice lacking endoglin (Eng/) die from car-
diovascular defects at midgestation (E10.5–11.5) with major
defects in yolk sac vasculature (6, 23, 103). In these embryos,
the first stages of differentiation from hemangioblasts to ECs
and the formation of the primitive vascular structures, a pro-
cess called vasculogenesis, occurs normally, but this primitive
system does not develop to a mature vascular network (angio-
genesis), indicating a critical role for endoglin in angiogenesis
rather than in vasculogenesis (80, 131).
Eng/ embryos also show a defective development of
VSMCs (103), and several explanations have been proposed to
account for this deficiency. First, the ectopic expression of
endoglin in neural crest stem cells causes pericardial hemor-
rhage associated with altered smooth muscle cell investment in
the walls of major vessels, suggesting a direct role for endoglin
in myogenic differentiation (115). Alternatively, in the yolk
sac, the absence of endoglin in ECs of Eng/ mice results in
a reduced availability of active TGF- protein to promote the
recruitment and the differentiation of mesenchymal cells into
VSMCs, thus leading to weak vessel walls (29). More recently,
it has been shown that endoglin, via the venous-specific marker
COUPTFII, plays distinct and cell-autonomous roles in VSMC
recruitment and arteriovenous specification in angiogenesis
that may contribute to HHT (114).
Endoglin haploinsufficient (Eng/) mice have been used to
investigate the function of endoglin in adult neovascularization
because these adult mice have endoglin protein levels reduced
by 50%, as in HHT1 patients (23, 77, 162). Eng/ mice have
a delayed reperfusion following hindlimb ischemia induced by
femoral ligation (79). Also, endoglin heterozygous mice im-
planted with Matrigel plugs, to measure EC outgrowth and
invasion into the ECM in vivo, showed significantly less
vascular structures compared with wild-type mice (79). More-
over, Eng/ mice with myocardial infarction induced by
coronary artery ligation showed a defective angiogenesis (168)
in agreement with data from a femoral artery-ligated hindlimb
model (79).
Endoglin and Tumor Angiogenesis
Most of the events occurring during “physiological” angio-
genesis also occur during the process of tumor angiogenesis.
Tumor vessels can exist either in an immature state (lack of
mural cells) or in association with pericytes/VSMCs. Angio-
genesis is a crucial process in tumor growth, as a continuous
supply of oxygen and nutrients is necessary to support the
anabolic cell metabolism involved in cell proliferation. In-
creased tumor size is accompanied by new vessel formation
stimulated by hypoxia and by the increased metabolism nec-
essary for tumoral cell growth. If angiogenesis is fully blocked,
tumor size cannot reach more than a few cubic millimeters.
Thus angiogenesis is considered as a major target for the
treatment of tumors.
Endoglin is overexpressed in tumor vessels (13, 25, 49, 56,
119) but also in tumor cells (4, 13). Endoglin is a better marker
of tumor capillary density than other classical markers of ECs,
and the assessment of microvascular density with endoglin
staining is a good prognostic indicator as it has been demon-
strated that the density of endoglin-positive blood vessels
negatively correlates with overall survival, disease-free sur-
vival, and metastasis in a great variety of solid tumors (re-
viewed in Ref. 13). Moreover, Eng/ mice bearing subcuta-
neous lung carcinomas show decreased tumor growth rates and
lower capillary densities compared with wild-type mice (50),
suggesting endoglin involvement in tumor growth (Fig. 4).
Given the high density of endoglin in tumor ECs, endoglin can
be also used to target these vessels with anti-endoglin antibod-
Fig. 3. Hypothetical model for the generation of arteriovenous malformations
in HHT. The capillary network subjected to the apoptotic stimuli, as shown in
Fig. 2, is not affected in normal subjects (A). However, in HHT patients (B and
C), as a consequence of the endothelial cell apoptosis, the capillary network
gradually disappears and only a preferential vessel remains that eventually
becomes the arteriovenous shunt (C).
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ies, bound or not to toxic substances, to destroy tumoral vessels
and limit tumor growth. In this regard, there are several
reported approaches using experimental animal models (55,
117, 156, 164, 165). Among these, the approach of using naked
anti-endoglin monoclonal antibodies as a tumor vascular tar-
geting agent is clinically relevant. In fact, a multicenter phase
I clinical trial using an anti-endoglin antibody (TRC105) has
been recently approved by the United States Food and Drug
Administration, and it is now in progress in patients with
advanced and/or metastatic cancer (13).
Endoglin and Regulation of Vascular Repair
Mononuclear cells (MNCs) contribute to the formation of
new blood vessels (7, 106, 140), and activated MNCs express
upregulated levels of endoglin (87). These findings prompted
van Laake et al. (168) to investigate whether endoglin expres-
sion in MNCs might regulate vascular repairing in an infarcted
myocardium by injecting MNCs from healthy human donors or
from HHT1 patients, which express half levels of endoglin.
MNCs from healthy human donors significantly improved
heart function in Eng/ mice, whereas MNCs from HHT1
patients were without significant effect (168). Because MNCs
from HHT1 patients showed a reduced homing ability to
infarcted mouse myocardium, the possible involvement of
stromal cell-derived factor-1 (SDF-1) and its corresponding
chemokine receptor CXCR4, which are crucial for homing and
are negatively influenced by CD26, were explored (132). Thus
it was shown that a decreased homing of HHT1-MNCs is
caused by an impaired ability of the cells to respond to
SDF-1. Interestingly, modulating the dipeptidyl peptidase IV
CD26 levels using inhibitors like diprotin A restored homing in
cases where an increased expression of CD26 contributes to the
underlying pathological mechanism (132).
The low angiogenic activity shown by Eng/ mice and the
abnormal behavior of MNCs from HHT1 patients in the heart
infarction experiments suggest a defective homing of endoglin-
expressing circulating cells. VEGF, in addition to directly
stimulating EC proliferation and migration, also induces the
expression of SDF-1, a chemokine that regulates MNCs
adherence to the vessel walls, where they can act in a paracrine
fashion to enhance proliferation of resident ECs (70). It should
be noted that VEGF production has been observed to be
decreased in ECs derived from Eng/ mice (79), and this
finding could explain the defects in MNC recruitment observed
in these animals. MNC adherence to the vessel wall is regu-
lated by a family of membrane molecules called cell adhesion
molecules (CAMs), including ICAM-1, VCAM-1, PECAM-1,
and P-selectin. After renal ischemia-reperfusion, both CAM
expression and MNC infiltration were reduced in Eng/
compared with wild-type mice (47). Thus a defective CAM
expression in endoglin-deficient cells (either in endothelial or
circulating cells) could also explain the low angiogenesis rate
associated with endoglin deficiency. TGF- also regulates the
formation of podosomes that are highly dynamic structures
involved in adhesion, migration, invasion, and circulating cell
recruitment (104, 120). As reduced endoglin expression affects
TGF- signaling in monocytes (88), this may lead to a defec-
tive podosome formation and impaired recruitment to inflamed
tissues.
Endoglin and Regulation of Vascular Tone
Mice deficient in endoglin (Eng/) show a defective vaso-
dilator response to endothelium-dependent vasodilator sub-
stances such as acetylcholine or bradykinin (77). In agreement
with these data, Eng/ mice show a decreased NO synthesis
and/or a decreased endothelial NO synthase (eNOS) expression
(77, 78, 160). However, opposite results have been reported, in
terms of vasodilation, using Eng/ mice. Thus Jerkic et al.
(77) observed a defective vasodilator response to acetylcholine
or bradykinin in the perfused hindlimb. By contrast, a de-
creased myogenic vasoconstrictory response and an increased
endothelium-dependent vasodilatation in phenylephrine-pre-
contracted mesenteric arteries have been reported (160). In
addition, the same group has reported that in pulmonary
arteries the endothelium-dependent relaxation in response to
acetylcholine of adult Eng/ mice was higher than that of
Eng/ control vessels (11). Accordingly, the interpretations
provided to explain these opposite results are also different. On
one hand, Jerkic et al. (77) postulate that the decreased vaso-
dilatation in Eng/ mice is due to a decreased NO production
as a consequence of decreased levels of eNOS. On the other
hand, while agreeing with a reduced NO production in these
animals, Toporsian et al. (160) hypothesize that endoglin
haploinsufficiency in ECs leads to the uncoupling of eNOS that
is associated with a defective eNOS/heat shock protein 90
(Hsp90) association and a subsequent decrease in NO release
and increase in O2 production (160). Because of the increased
levels of O2, these authors explain the increased vasodilatory
response in Eng/ mice based on the fact that O2 has been
reported to directly inhibit smooth muscle contraction in vitro
(82) and that the H2O2, generated from O2 by dismutation, is
a vasorelaxant in mouse mesenteric arteries. However, a wide
number of studies have shown that O2 decreases endothelium-
dependent vasodilatation as it removes NO upon chemical
reaction, producing peroxinitrites (137). In addition, endoge-
nous H2O2 may act as a vasoconstrictor in murine resistance
vessels (154), although other studies have shown that H2O2 is
a major endothelium-dependent relaxing factor in mice aorta
(27) or cerebral arteries (48).
Because some of these studies were performed in perfused
hindlimbs (77) and others in isolated mesenteric arteries (160),
a possible explanation for these contradictory results is that the
Fig. 4. Role of endoglin in tumor vascular endothelium. In vivo and in vitro
studies support the involvement of endoglin in tumor suppression and pro-
gression, modulating angiogenesis and tumor proliferation. Increased endoglin
expression correlates with increased tumor angiogenesis, probably because of
the proangiogenic role of endoglin in endothelial cells.
Review
H964 ENDOGLIN IN THE CARDIOVASCULAR SYSTEM
AJP-Heart Circ Physiol • VOL 299 • OCTOBER 2010 • www.ajpheart.org
responses and mechanisms involved in endothelium-dependent
vascular relaxation may vary with the different vascular beds
and the specific experimental approach. For instance, in mouse
mesenteric arteries, a chronic rise in blood flow induces a
diameter enlargement involving NO and O2 (37), a finding
compatible with the myogenic response data of Toporsian et al.
(160). Moreover, the infusion of mice with angiopoietin II,
characterized by a hyperproduction of O2 and ONOO, causes
an impairment in the NO-mediated component of endothelium-
dependent relaxation in response to acetylcholine. This inhib-
itory effect is mediated by increased O2 and ONOO in the
VSMCs of mesenteric arteries (174), at variance with the
increased endothelium-dependent vasodilatation of mesenteric
arteries reported in Eng/ mice (160).
Regarding muscular arteries that are involved in the hind-
limb perfusion experiments of Eng/ animals (77), it has been
reported that mice fed a high-salt diet show an increased
generation of O2 in the skeletal muscle microcirculation and
an impaired endothelium-dependent dilation through reduced
NO bioavailability. Specifically, arteriolar dilation in response
to acetylcholine was 50% smaller in high-salt mice than in
normal-salt mice, whereas the inhibition of NO synthase
(NOS) with NG-monomethyl-L-arginine significantly reduced
the resting diameters and responses to acetylcholine in normal-
salt mice but not in high-salt mice (124). These data are in
agreement with the defective vasodilator response to acetyl-
choline in the perfused hindlimb of Eng/ mice (77).
With respect to pulmonary arteries and the pathogenesis of
pulmonary hypertension, an increased production of NO in
eNOS transgenic mice prevented the increase in right ventric-
ular systolic pressure, lung vascular remodeling, and right
ventricular hypertrophy induced by chronic hypoxia, thus sug-
gesting that a decreased eNOS production contributes to the
pathogenesis of pulmonary hypertension (127). Furthermore, a
decreased eNOS/Hsp90 interaction has been suggested to play
a role in the pathogenesis of hypoxia-induced pulmonary
hypertension on the basis of decreased eNOS activity and NO
bioavailability (84, 122), a result that is in agreement with the
pulmonary hypertension observed in Eng/ mice (161). How-
ever, a recent study in lungs of caveolin knockout mice showed
that an increased eNOS/Hsp90 interaction was involved in the
mechanism of pulmonary hypertension because of the persis-
tent activation of eNOS and the resultant increased formation
of ONOO (178). Thus high levels of O2 and ONOO,
similarly to those reported in Eng/ mice (160), decreased
NO availability and led to the nitration of PKG, a critical
mediator of the NO-dependent vasodilatation. Consequently,
an impaired endothelium-dependent relaxation was observed
(178), as opposed to the increased endothelium-dependent
vasodilatation found in Eng/ mice (160), although both
animal models share the pulmonary hypertension phenotype
(161, 178).
Taken together, these data provide evidence that there is a
dysregulated vascular tone in endoglin-deficient animals, while
underlining the complexity in the regulation of the vascular
tone by NO, O2 and their derivatives and in the pathways
present in different vascular beds, which may explain the
apparently discrepant results observed in the Eng/ mice by
different groups.
TGF-1 leads to an increased vasodilatation in control mice
that is severely impaired in Eng/ mice, suggesting the
involvement of endoglin in the TGF--regulated vascular ho-
meostasis (147). The decreased vasodilatation shown by
Eng/ mice is not associated with increased arterial pressure
because these animals also show increased cyclooxygenase-2
(COX-2) expression and activity with the corresponding in-
crease in the production of COX-2-derived vasodilator eico-
sanoids (78). Accordingly, the simultaneous inhibition of
COX-2 and NOS markedly increases arterial pressure in
Eng/ mice (78).
The altered vasodilator response in endoglin-deficient ani-
mals suggests a potential mechanism in the genesis of AVMs
present in HHT1 patients. Under normal conditions, NO reg-
ulates the dilatation of precapillary sphincters. However, if this
mechanism is impaired, the precapillary sphincters remain
closed, whereas the blood circulates only through the prefer-
ential ways, lacking precapillary sphincters, existing in the
capillary beds. This could lead to capillary EC apoptosis
induced by hypoxia and may be reinforced by endoglin hap-
loinsufficiency as in HHT1. At the same time, the preferential
ways may react to the increased flow by widening their
diameter and recruiting smooth muscle cells (arterialization),
thus leading to the typical vascular malformations. This hy-
pothesis is supported by the observation that adult Eng/
mice display pulmonary arterial hypertension accompanied by
a rarefaction of peripheral vessels and dilatation of central
large vessels (161). It should be noted that the lung is a
frequent place for arteriovenous shunts in HHT1 patients (69,
74). Further support for a dysregulated vascular tone in HHT
has been recently reported (11). Adult, but not newborn,
Eng/ mice show pulmonary vascular eNOS uncoupling. In
agreement with this finding, pulmonary arteries from adult
Eng/ mice are more dilated and have an enhanced endothe-
lium-dependent smooth muscle relaxation potential. This in-
creased vasorelaxation may play a role in the formation of
pulmonary AVMs later in life and could explain the generally
late onset of pulmonary clinical manifestations in HHT (11). In
summary, these results further support a role for endoglin in
the regulation of vascular tone.
NO Mediates Endoglin Involvement in Angiogenesis
and Vascular Homeostasis
NOS-derived NO is a major regulator of vascular tone and
angiogenesis following arterial occlusion. The ischemic tissue
shows an increase in eNOS mRNA, protein expression, and
NO synthesis (77, 109). The deficiency of the NO pathway
either by pharmacological inhibition or by gene disruption of
eNOS diminishes ischemia-induced angiogenesis. Conversely,
a supplementation of NO by the use of exogenous sources
restores ischemia-induced angiogenesis. (109).
The transcription of eNOS is regulated by endothelial sheer
stress, hypoxia, several hormones, and various mediators and
growth factors, including TGF-1. Endoglin plays a major role
in regulating eNOS abundance and NO synthesis. The endog-
lin-dependent regulation of eNOS abundance seems to be
based on two different mechanisms. First, endoglin regulates
eNOS mRNA expression (77, 78, 147). Thus Eng/ mice and
ECs derived from these mice show reduced levels of both basal
and TGF-1-induced eNOS mRNA and protein levels, without
changes in inducible or neuronal NOS (77, 78, 160). Further-
more, the ectopic expression of endoglin in ECs in vitro results
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in increased levels of Smad2 protein, leading to an enhanced
TGF- receptor-dependent induction of eNOS mRNA expres-
sion (147). The second mechanism involved in the regulation
by endoglin of eNOS abundance is the regulation by endoglin
of the half-life of eNOS protein and eNOS activity (160). In
this regard, functional ECs lacking endoglin lose the capacity
to generate NO in response to calcium-dependent eNOS acti-
vation. Thus endoglin associates with eNOS and Hsp90 and
stabilizes the activation complex, resulting in NO production
(Fig. 5A). In addition, eNOS activity was reported to be
uncoupled in Eng-deficient murine ECs, as evidenced by a
severely reduced eNOS/Hsp90 association and an increased
eNOS-derived O2, H2O2, and, presumably, ONOO produc-
tion (Fig. 5B). Accordingly, it has been suggested that endoglin
modulates the coupling of eNOS activity by acting as a
scaffolding protein and bringing cytoplasmic Hsp90 into close
proximity with caveolar eNOS (160). Furthermore, it has been
reported that in Eng/ mouse tissues and in Eng/ cells,
eNOS is uncoupled, leading to a decreased NO availability and
increased O2 and H2O2 production (11, 161).
These findings suggest that endoglin expression and NO
regulation are intimately related. Consequently, a major role
for eNOS in endoglin-dependent angiogenesis and vascular
tone has been postulated. A demonstration of the importance of
NO in mediating the stimulation of angiogenesis by endoglin
comes from the fact that a blockade of NO synthesis with
N-nitro-L-arginine methyl ester (L-NAME) decreases angio-
genesis after hindlimb ischemia in normal mice but not
in endoglin-deficient mice (79). Similar results were observed
in a model of tumor-induced angiogenesis in Eng/ mice. In
these mice, tumor growth and vessel density was lower than in
control mice (50). Also, NO synthesis blockade with L-NAME
induced a marked inhibition of angiogenesis in control mice
that was much lower in Eng/ mice (A. Duwell, N. Eleno, C.
Bernabeu, and J. M. López-Novoa; unpublished data). Taken
together, these data support the hypothesis that eNOS-derived
NO plays a major role in the endoglin-dependent regulation of
angiogenesis and vascular tone.
Endoglin, the TGF- Signaling Pathway, and Vascular
Homeostasis
TGF- superfamily members, including bone morphoge-
netic protein (BMP), activin, and TGF- subfamilies, criti-
cally regulate many different processes within the car-
diovascular system, including cardiac development and
angiogenesis. The importance of TGF- signaling in the
cardiovascular system is underlined by the observation that
the genetic deletion of several TGF- family members, their
receptors, or downstream signaling proteins in mice results
in the death of most of the mutants because of severe defects
in yolk sac vasculature formation (67). Also, alterations in
this pathway, including either germ-line mutations or alter-
ations in the expression of members of these signaling
pathways, may lead to cardiovascular pathology (40, 62, 66,
157).
Members of the TGF- superfamily signal through specific
cell surface receptor complexes containing a heterodimeric
association between signaling receptors types I and II and
nonsignaling type III receptors or coreceptors. The receptors
types I and II are serine/threonine kinases and are involved in
the downstream signaling, whereas the coreceptors, including
endoglin and betaglycan, are proteins without known signaling
motifs. The core TGF- signaling pathway comprises at least
seven type I (also known as ALK receptors) and five type II
receptors, where type I acts downstream of type II and whose
combinatorial heterodimeric association determines the speci-
ficity of the ligand signaling. The type I receptors include BMP
(ALK1, ALK2, ALK3, and ALK6), activin (ALK1, ALK2, and
ALK4), and TGF- (ALK1, ALK2, and ALK5) receptors.
Upon ligand binding, the type II receptor transphosphorylates
the type I receptor, which subsequently propagates the signal
by phosphorylating the receptor-regulated Smad (R-Smad; and
Smad1, -2, -3, -5, and -8) family of proteins. Once phosphor-
ylated, R-Smads form heteromeric complexes with a cooper-
ating homolog named Co-Smad (Smad4) and translocate into
the nucleus where they regulate the transcriptional activity of
target genes. (62, 116, 157).
Fig. 5. Hypothetical model on the role of endoglin in
endothelial nitric oxide (NO) synthase (eNOS) expres-
sion and activation. A: in Endoglin/ cells, a pool of
endoglin resides in caveolae, a cholesterol-rich plasma
membrane domain containing caveolin and eNOS.
Endoglin acts as a molecular scaffold facilitating cal-
cium-bound calmodulin and heat shock protein-90
(Hsp90) association to eNOS during endothelial acti-
vation (160), thus producing normal amounts of NO
and the consequent vasodilatation. B: in endoglin
haploinsufficiency (Endoglin/), both the amount of
eNOS (77, 78) and the eNOS/Hsp90/calmodulin asso-
ciation are reduced, leading to decreased NO as well
as increased eNOS uncoupling and formation of
eNOS-derived superoxide anion (O2) (160). In turn,
O2 produces hydrogen peroxide (H2O2) by dismuta-
tion (11, 161) and presumably reacts with NO to
generate peroxynitrite (ONOO). Thus the removal of
the vasodilator NO and the presence of oxygen free
radicals results in an impaired vasomotor tone.
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Endoglin forms a protein complex with the TGF- type I
(ALK1 and ALK5) and type II receptors and the ligand (14, 30,
73). Several members of the TGF- superfamily, including
TGF-1 and TGF-3 (but not TGF-2) activin-A, BMP-7, and
BMP-2, are able to bind endoglin, and this binding requires the
presence of the corresponding signaling receptors (8, 30, 96).
By contrast, endoglin is able to bind BMP-9 in the absence of
signaling receptors (149), in agreement with the endoglin-
dependent increase of the cellular response to BMP-9 (40).
Interestingly, BMP-9 has also been shown to be a specific
ligand of ALK1. Among the BMP-9-dependent effects are the
inhibition of EC proliferation and migration in vitro, as well as
the inhibition of neoangiogenesis in vivo (40–42, 166). These
BMP-9 effects appear to be mediated by a receptor complex
formed by ALK1, the BMP receptor type II, and endoglin (40).
Endoglin modulates ligand binding and signaling by an asso-
ciation with ALK1 and ALK5. These type I receptors activate
signaling pathways via Smad1, -5, and -8 (ALK1) or Smad2
and -3 (ALK5) to regulate, among others, the proangiogenic
inhibitor of DNA binding 1 (Id1) or PAI-1 target genes,
respectively. The balance between ALK1 and ALK5 signaling
pathways in ECs and VSMCs plays a crucial role during
vascular remodeling and angiogenesis, although the exact mo-
lecular mechanisms remain to be elucidated (41, 93, 126, 151,
157). In the ALK1/ALK5 setting, endoglin inhibits the TGF-
/ALK5/Smad3-mediated cellular responses (15, 71, 92, 96,
150, 169) and enhances ALK5/Smad2-mediated responses (29,
73, 147). In addition, endoglin promotes TGF-1/ALK1 (15,
92) and BMP-9/ALK1 (40) signaling in ECs. Also, endoglin
enhances the BMP-7 signal via Smad1/Smad5 pathway in
myoblasts (150). Thus endoglin appears to be a critical mod-
ulator of the balance between ALK1 and ALK5 signaling (92).
The mechanism by which endoglin potentiates TGF-/ALK1
signaling involves the direct association of ALK1 with the
cytoplasmic and extracellular domains of endoglin, whereas
the extracellular domain mediates the enhancement of ALK1
signaling (15). These studies support the view that endoglin
and ALK1 participate in a common signaling pathway that is
critical for EC responses to TGF- family members. This
conclusion agrees with the fact that pathogenic mutations in
endoglin or ALK1 genes result in HHT (1) and that ALK1 and
endoglin null mice have similar vascular phenotypes (6, 23,
103, 126, 153). The extracellular and cytoplasmic domains of
endoglin also interact with ALK5 and the type II receptor, but
ALK5 interacts with the endoglin cytoplasmic domain only
when the kinase domain is inactive. Upon association, ALK5
and the type II receptor phosphorylate the endoglin cytoplas-
mic domain; ALK5, but not the type II receptor, then dissoci-
ates from the complex (73). These data suggest the hypothesis
that the extracellular and cytoplasmic domains of endoglin play
distinct roles in receptor signaling that are downstream of
ligand binding and receptor activation.
Role of Other Endoglin Forms in Vascular Physiopathology
S-endoglin isoform. The endoglin data described in the
previous sections of this review are referred to the most
abundant form of endoglin, the membrane-bound full-length
L-endoglin. However, another isoform of membrane endoglin
has been described, which is generated by an alternative
splicing of the same gene, giving rise to S-endoglin (12, 130).
In humans, S-endoglin protein contains a cytoplasmic domain
that is 33 amino acids shorter than that of L-endoglin (Fig. 1B).
Comparative studies between L-endoglin and S-endoglin have
revealed distinct functions for each isoform. Thus S-endoglin
seems to have an antiangiogenic effect, in contrast to the
proangiogenic role attributed to L-endoglin. Mice transgenic
for human S-endoglin (170) exhibit a deficient angiogenic
phenotype that drives to a significant delay in tumor growth
(130), similar to that shown by mice deficient in L-endoglin
(50, 136). S-endoglin is also involved in the senescence of
ECs. The ratio of S-endoglin to L-endoglin isoforms is in-
creased during the senescence of human ECs in vitro, as well
as during the aging of mice in vascularized tissues (14).
Furthermore, transgenic mice overexpressing S-endoglin in
ECs showed hypertension, decreased hypertensive response to
NO inhibition, decreased vasodilatory response to TGF-1,
and decreased eNOS expression in lungs and kidneys, support-
ing the involvement of S-endoglin in the NO-dependent vas-
cular homeostasis (14). These results suggest that S-endoglin is
induced during endothelial senescence and may contribute to
age-dependent vascular pathology.
Signaling by S-endoglin seems to be also different from that
by L-endoglin. In myoblasts and ECs, L-endoglin enhanced the
ALK1/Id1 pathway, whereas S-endoglin promoted the ALK5/
PAI-1 route (14, 169). These effects on signaling are supported
by the biological effects on TGF-1-induced collagen-I ex-
pression and the inhibition of cell proliferation. Thus, whereas
L-endoglin decreased TGF-1-induced collagen-I and connec-
tive tissue growth factor expression and increased TGF-1-
induced proliferation, S-endoglin strongly increased TGF-1-
induced collagen-I and connective tissue growth factor expres-
sion and reduced TGF-1-induced cell proliferation (169). The
mechanism underlying the different behavior of S- and L-
endoglin might reside in their different interaction with the
signaling TGF- receptors. In ECs, S-endoglin interacts with
both ALK5 and ALK1, although the interaction with ALK5 is
stronger than with ALK1 (14), at variance with L-endoglin that
shows a higher affinity for ALK1 versus ALK5 (15). More-
over, S-endoglin behaves differently than L-endoglin in rela-
tion to several TGF--responsive specific reporter constructs
with different specificities. Thus S-endoglin expression in-
creased the ALK5 signaling pathway, whereas L-endoglin
inhibited the same pathway. On the other hand, L-endoglin, but
not S-endoglin, stimulated the ALK1 signaling pathway (14,
169). These results suggest that the S-endoglin-to-L-endoglin
ratio in ECs may contribute to balancing the TGF- signal
through ALK5 or ALK1 and their important roles in vascular
pathophysiology (Fig. 6).
A role for S-endoglin in the regulation of vascular tone has
been postulated. Mice transgenic for human S-endoglin (S-
Eng) show a defective NO synthesis and a decreased eNOS
expression in lungs and kidneys (14), in contrast with the
positive relationship between levels of L-endoglin and eNOS
previously reported in both mice and cultured ECs (77, 78,
160). However, at variance with Eng/ mice, in which the
arterial pressure was normal, S-Eng mice were hypertensive
(14). Furthermore, in both cultured ECs and endoglin-deficient
mice, low levels of L-endoglin are associated with high COX-2
expression (77), and this increased COX-2 expression is also
found in tissues from S-Eng mice (14). Moreover, S-Eng
transgenic mice show a reduced hypotensive response to
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TGF-1 administration (14). This observation is in agreement
with the finding that TGF-1 regulates eNOS expression (148)
and induces vasodilatation in wild-type mice, this vasodilata-
tion being severely impaired in Eng/ mice (147). Thus an in
vivo overexpression of S-endoglin appears to result in the same
phenotype as L-endoglin deficiency, suggesting opposing func-
tional effects of both isoforms on the NO and COX-2 systems.
Soluble endoglin. A soluble form of endoglin (sEng) has
been detected by ELISA and Western blot analysis in plasma,
serum, and urine from patients with different pathologies,
including preeclampsia and cancer. Circulating sEng has been
purified from preeclampsia patients, and its partial peptide
sequence suggests that it is an NH2-terminal cleavage product
of full-length membrane-bound endoglin (172).
Preeclampsia is a systemic syndrome of pregnancy clinically
characterized by a new onset of proteinuria and hypertension
associated with significant morbidity and mortality to both
mothers and fetuses. In these patients, sEng plasma levels are
upregulated in a pattern similar to that of a soluble VEGF
receptor known as soluble fms-like tyrosine kinase-1 (sFlt1)
(97, 172). Interestingly, levels of cell surface endoglin are
significantly increased in preeclamptic placentas (97). Because
endoglin is expressed at high levels in the syncytriotrophoblast
and invading cytotrophoblasts (65) and membrane-type metal-
loprotease-1 (MT1-MMP or MMP-14) is expressed in tropho-
blasts (175), it has been postulated that increased sEng levels in
preeclampsia derive from the proteolytic action of MT1-MMP
on the full-length membrane-bound endoglin expressed in
trophoblasts or in nearby cells (107) (Fig. 7). Experimental
support for this hypothesis has been recently reported, demon-
strating that MT1-MMP is in fact a major endoglin-shedding
protease (75). This is compatible with the fact that -glycan,
another TGF- coreceptor with a partial sequence homology to
endoglin, can be shed by MT1-MMP (171). Of note, increased
levels of membrane-bound endoglin have also been reported in
circulating cells of women with preeclampsia, thus suggesting
that this is not only a local, but a systemic, endoglin upregu-
lation (134). It has been shown that uterine ischemia and/or
hypoxia plays a major role in increased sEng release. In an
experimental model with pregnant rats, placental ischemia
induced by a reduction of uterine perfusion pressure increases
the expression of sEng and provokes hypertension, thus mim-
icking the pathophysiological features of preeclampsia (61).
Compatible with these findings, women with preeclampsia
have alterations in placental HIF-1 and its targets (138), and
hypoxia has been shown to upregulate the expression and
secretion of sFlt1 protein in primary trophoblast cultures from
first-trimester placentas (123). Hypoxia has been shown to
upregulate endoglin expression in ECs (146, 179), although
this upregulation was not observed in cultured villous thropho-
blasts (121). Preeclampsia has been attributed to increased
oxidative stress in the placenta (139), whereas heme oxygen-
ase-1 (HO-1) and its metabolite carbon monoxide exert pro-
tective effects against oxidative stimuli (39). In this regard, it
has been reported that an overexpression of HO-1 in ECs
inhibited VEGF-mediated sFlt-1 release and interferon-- and
tumor necrosis factor--induced sEng release, whereas HO-1
inhibition potentiated sFlt-1 and sEng production from ECs
and placental villous explants. Furthermore, mice lacking
HO-1 produced higher levels of sFlt-1 and sEng compared with
wild-type mice (39).
In addition to being a reliable biomarker of the disease, it has
been suggested that sEng plays a major role as an antiangio-
Fig. 6. Hypothetical model of S-endoglin functions during
endothelial senescence. In the normal state, the TGF-
response is modulated by L-endoglin, but upon senescence
of endothelial cells, S-endoglin is upregulated, interacting
with the TGF- receptor complex containing activin-like
kinase 1 (ALK1) and ALK5. As a consequence of this
interaction, S-endoglin regulates the expression of different
target genes including plasminogen activator inhibitor type
1 (PAI-1), inhibitor of DNA binding 1 (Id1), eNOS, and
cyclooxygenase-2 (COX-2). Thus S-endoglin allows a
switch that triggers the cardiovascular pathology: 1) up-
regulation of PAI-1/extracellular matrix (ECM) synthesis
may lead to increased fibrosis, 2) downregulation of Id1 is
associated with decreased angiogenesis, and 3) downregu-
lation of eNOS and upregulation of COX-2 are involved in
endothelial dysfunction and impaired vascular relaxation.
The involvement of TGF- receptor type II (TRII),
TGF-, and S-endoglin/L-endoglin heterodimers has been
omitted for simplification. Adapted from Blanco et al. (14)
and used with permission.
Fig. 7. Generation of soluble endoglin by proteolytic processing of membrane-
bound endoglin. A recent report suggests that membrane-type metallopro-
tease-1 (MT1-MMP) is a major endoglin-shedding protease acting on the
juxtamembrane region and leading to the secretion of the large ectodomain of
endoglin (75). Several functions reported for soluble endoglin are indicated.
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genic factor in preeclampsia. Thus sEng amplifies the vascular
damage mediated by sFlt1 in pregnant rats, inducing a severe
preeclampsia-like syndrome with features of the hemolysis-
elevated liver enzymes and low platelet syndrome (172). More-
over, an overexpression of sFlt1 and sEng in rodents was found
to induce focal vasospasm, hypertension, and increased vascu-
lar permeability that were associated with brain edema, pro-
ducing images reminiscent of reversible posterior leukoen-
cephalopathy associated with human eclampsia (111). This
effect may be mediated by the interference of the NO-mediated
vasodilation. In vitro studies demonstrate that sEng impairs EC
proliferation and capillary formation (172). Interestingly, the
angiogenic process is disturbed in preeclamptic placentas, thus
suggesting that sEng has antiangiogenic properties. Compati-
ble with this finding, it has been shown that an injection of
sEng in rats induced hypertension (172). To explain the mech-
anism involved, it has been proposed that sEng plays its
antiangiogenic and prohypertensive effects through an interac-
tion with circulating endoglin-binding molecules, such as the
TGF- protein superfamily, thus preventing the binding of
these molecules to the cell membrane TGF- receptor complex
(108). In fact, in vitro studies have shown that sEng inhibits
TGF-1 signaling and competes for TGF-1 binding to its
receptors, abolishing ALK5 signaling-dependent responses in
ECs and consequently the proangiogenic effects of TGF-1 in
the normal endothelium (172). Of note, the short form of
membrane endoglin (S-endoglin), with only 14 amino acids in
its cytoplasmic domain, shows opposite effects to the proan-
giogenic L-endoglin isoform (14, 130, 169), supporting a
critical role for the extracellular domain in this process. An-
other possible mechanism involved in the antiangiogenic ef-
fects of sEng is based on its inhibitory effect on TGF-1-
mediated eNOS activation in ECs (172). Thus, while there is an
increased NO synthesis in pregnant rats, evidence for NO
deficiency in preeclampsia has been obtained from experimen-
tal rat models of preeclampsia. Endothelial dysfunction has
been reported in women with preeclampsia. Accordingly, it has
been postulated that preeclampsia is a disease with a major
endothelial dysfunction component that plays a role in pre-
eclampsia-associated hypertension (43, 173). Endothelial dys-
function in preeclampsia has also been attributed to placental
oxidative stress, the excess production of damaging reactive
oxygen species, as markers of high oxidative stress are de-
tected in preeclamptic placentas (134). A key animal model of
preeclampsia is produced by infusion of the NO synthesis
inhibitor of L-NAME in pregnant rats, leading to hypertension,
proteinuria, and thrombocytopenia (176). As described in NO
Mediates Endoglin Involvement in Angiogenesis and Vascular
Homeostasis, decreased NO synthesis is associated with de-
creased angiogenesis, as occurs in endoglin-deficient mice (77,
78, 147), suggesting that sEng behaves as an antagonist of
L-endoglin in endothelium-dependent responses such as angio-
genesis. Supporting this view, sEng inhibits the proangiogenic
activity of VEGF, another protein that plays a major role in
angiogenesis (54, 75).
sEng also seems to be a regulator of vascular tone. It has
been reported that the administration of sEng to mice induces
an increase in arterial pressure by increasing vascular resis-
tance (172). Most probably, this effect could be attributed to
the inhibitory effect of sEng on TGF-1-mediated eNOS
activation in ECs, and it has been suggested that high levels of
circulating sEng might contribute to the hypertension shown by
women with preeclampsia (172). Thus these data suggest that
sEng behaves as an antagonist of L-endoglin in endothelium-
dependent responses such as vasodilatation and angiogenesis.
Recently, a role for sEng in brain AVMs has been postu-
lated. Thus patients with brain AVMs had higher mean sEng
levels compared with controls (32). To determine whether
sEng affects the vasculature of the adult mouse brain, an
injection of adenovirus-expressing human sEng into brain
areas previously exposed to adeno-associated virus expressing
VEGF was carried out. Indeed, an increased number of dys-
plastic blood vessels associated with increased membrane-type
matrix metalloprotease-2 (MMP-2) and MMP-9 activity were
revealed in the sEng-treated animals (172). These results sug-
gest that elevated sEng may play a role in the generation of
sporadic brain AVMs and may provide new targets for a
therapeutic intervention in patients with brain AVMs.
In addition to preeclampsia and brain AVMs, altered sEng
levels have been reported in several pathologies such as cancer
(13, 26, 99), atherosclerosis and coronary artery disease (16,
102), hepatitis (34), diabetes (5), systemic sclerosis (44, 58),
malaria (45), biliary atresia (133), or sickle cell disease (86).
Interestingly, a number of laboratories have reported increased
levels of sEng in serum, plasma, or other fluids from cancer
patients as a marker of poor prognosis [reviewed by Fonsatti et
al. (56) and Bernabeu et al. (13)]. Also, it has been reported
that changes of sEng plasma levels after an acute myocardial
infarct are accurate predictors of acute mortality in these
patients (38). Although there are numerous reports on the
possible participation of sEng in different diseases, the specific
molecular mechanism of action of this soluble form of endog-
lin in these pathologies remains to be elucidated.
Taken together, these results suggest that both the mem-
brane-bound short isoform (S-endoglin) and the soluble endog-
lin are involved in several pathological conditions and play
opposite roles with respect to the predominant membrane-
bound L-endoglin isoform.
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